- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jeff White: Best Practices for Preventing Opioid Misuse
Jeff White, PharmD, MS, staff vice president, Anthem, outlines best practices for preventing opioid misuse.
Jeff White, PharmD, MS, staff vice president, Anthem, outlines best practices for preventing opioid misuse.
Transcript
What are some best practices for opioid management in order to prevent misuse?
Best practices include hard policies to help ensure clinically appropriate use. For example, 7-day supply limit for individuals newly starting on a short-acting opioid. Also, prior authorization for individuals newly starting on a long-acting opioid therapy. Also, medication assisted therapy, such as buprenorphine and naltrexone, should be made available, and also making available the rescue antidote called naloxone for those who are high risk for overdose.
Additional best practices include monitoring and understanding use patterns by prescribers and patients and developing and implementing programs that help guide clinically appropriate therapy.
Understanding TB Symptoms, Spread, Treatment Amid Kansas City Outbreak
February 13th 2025In part 2 of this interview, Michael A. Bernstein, MD, highlights the need for prolonged antibiotics and strong public health measures to combat tuberculosis (TB) at both the individual and population levels.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”
February 7th 2025Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from the 2021 FDA approval of aducanumab (Aduhelm) and use of the accelerated approval pathway.
Read More
